What happened
IOVA stock gained 36.16% during regular trading on September 29, 2026, closing at $14.95. Volume hit 56.2 million shares, more than 4.7 times the average daily volume of roughly 11.7 million shares. The move came after Iovance Biotherapeutics issued a full-year 2026 revenue guidance revision during the trading session.
Why the stock moved
Iovance Biotherapeutics raised its 2026 revenue guidance to $410-$420 million, up from prior expectations, driven by accelerating demand for Amtagvi. The company disclosed the guidance in a press release carried by GlobeNewsWire on September 29, 2026. Benzinga reported that Amtagvi demand specifically underpinned the upward revision. This marks a notable commercial inflection for the melanoma therapy that won FDA approval in early 2024.
The numbers
- Price gain: +36.16% (from $10.98 to $14.95)
- Session volume: 56,243,508 shares
- Avg. daily volume: ~11,730,216 shares
- Market cap: $5.35 billion
- Shares outstanding: 357,533,242
- Short interest: 87,127,871 shares, 7.43 days to cover
IOVA price, filings, and news on Vantafin
What to watch
Investors should monitor whether the Amtagvi prescription curve continues to accelerate in the coming quarters. Iovance has phase 2 readouts pending from its C-144-01 melanoma study and its LN-145 program for head and neck squamous cell carcinoma, with data expected before year-end 2026. Any update on payer coverage decisions or label expansions could shift the revenue trajectory higher or lower. The elevated short interest means any positive catalyst tends to produce outsized moves, as short covering amplifies the initial gain.